2024-511503-41-00招募中1 期
This study aims to find the best dose of BI 907828 (brigimadlin) in patients with different types of advanced cancer (solid tumors)
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.14 个研究点 分布在 6 个国家目标入组 112 人开始时间: 2024年9月26日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 112
- 试验地点
- 14
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
CT Disclosure & Data Transparency
Scientific
Boehringer Ingelheim International GmbH
研究点 (14)
Loading locations...
相似试验
撤回
1 期
This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With VenetoclaxLeukemia, Lymphocytic, Chronic, B-CellNCT03343678Boehringer Ingelheim
已完成
1 期
BN80927 in Patients With Advanced Malignant Solid TumorsMalignant Solid TumourNCT01435096Ipsen56
已完成
2 期
Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)Pulmonary Disease, Chronic ObstructiveNCT00696020Boehringer Ingelheim360
已完成
1 期
A Multiple Dose Safety Study of PEG-IFN in Healthy VolunteersHealthyNCT02125578Biogen69
已完成
2 期
Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD)Pulmonary Disease, Chronic ObstructiveNCT00720499Boehringer Ingelheim141